Emergent BioSolutions
Tracked across 3 events · 21 articles · First seen Apr 29, 2026 · Last active Sep 10, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Emergent BioSolutions is the subject of the investigation. The company reduced its FY2026 revenue and EBITDA guidance and recorded a $191.3 million impairment on Naloxone, leading to a sharp stock decline and potential legal liabilities.
Aug 10, 2026 · 6 articles
Regulatory
Pomerantz LLP LLP announced it is investigating claims on behalf of investors of Emergent BioSolutions Inc. concerning whether the company and certain of its officers and/or directors engaged in securities fraud or other unlawful business…
Impact: Emergent is the subject of the securities fraud investigation and the company whose impairment charge, guidance cut, and 29.58% stock drop triggered it. The probe raises the risk of litigation costs and further reputational damage.
Aug 25, 2026 · 8 articles
Business
Impact: Emergent BioSolutions, the manufacturer of Narcan (naloxone) nasal spray, partnered with Davis Schneider to promote awareness and availability of naloxone, potentially increasing its market reach and public perception.
Apr 29, 2026 · 7 articles
90
Emergent BioSolutions reported quarterly resultsPomerantz Investigates...
80
Emergent BioSolutions cut revenue guidancePomerantz Investigates...
70
Emergent BioSolutions stock price fell New York Stock ExchangePomerantz Investigates...
60
Pomerantz LLP investigates claims Emergent BioSolutionsPomerantz Investigates...
ERGEN INTELLIGENCE
Track Emergent BioSolutions live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard